ARS Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $15,717 | $7,973 | $86,581 | $2,068 |
Gross Profit | 10,733 | 6,879 | 85,716 | 1,956 |
EBITDA | -44,604 | -35,496 | 47,197 | -21,748 |
EBIT | -44,883 | -37,177 | 47,226 | -21,769 |
Net Income | -44,883 | -33,940 | 49,934 | -19,128 |
Net Change In Cash | 15,717 | 7,973 | 86,581 | 2,068 |
Free Cash Flow | -39,643 | -40,833 | 41,702 | -14,607 |
Cash | 51,540 | 39,864 | 50,817 | 39,657 |
Basic Shares | 98,361 | 98,060 | 97,954 | 97,032 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $89,149 | $30 | $1,316 | $5,506 |
Gross Profit | 88,172 | 30 | 997 | 5,293 |
EBITDA | -2,875 | -67,447 | -34,363 | -19,241 |
EBIT | -3,083 | -67,520 | -34,682 | -19,454 |
Net Income | 7,998 | -54,365 | -34,682 | -20,243 |
Net Change In Cash | 89,149 | 30 | 1,316 | 5,506 |
Cost of Revenue | 150,455 | |||
Free Cash Flow | 12,985 | -59,441 | -40,277 | -17,616 |
Cash | 50,817 | 70,971 | 210,518 | 60,063 |
Basic Shares | 102,390 | 95,215 | 39,956 | 28,872 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.46 |
2025-03-31 | -$0.35 |
2024-12-31 | $0.51 |
